Literature DB >> 27531085

National Trends in Deep Vein Thrombosis following Total Knee and Total Hip Replacement in the United States.

Anahita Dua1, Sapan S Desai2, Cheong J Lee1, Jennifer A Heller3.   

Abstract

BACKGROUND: Total knee replacement (TKR) and total hip replacement (THR) are associated with an increased risk of deep vein thrombosis (DVT). Advances in DVT prophylaxis over the past decade have led to a decrease in DVT-related morbidity, but gender, racial, and other demographic factors that contribute to a higher risk of DVT are incompletely characterized. This study aimed to determine the incidence of DVT over the past decade and identify factors that were associated with an increased risk of DVT.
METHODS: Patients who underwent TKR or THR between 2001 and 2011 were identified using the National Inpatient Sample. For patients who developed a DVT, their demographics (including age, gender, and race), comorbidities, and subsequent outcomes (including length of stay [LOS] and mortality) were determined. Differences between patients who developed a DVT and those who did not were determined using multivariate regression analysis. A Mann-Kendall analysis was done to evaluate all trends.
RESULTS: Between 2001 and 2011, a total of 1.1 million patients underwent TKR, and 550,000 underwent THR. The overall incidence of DVT decreased for TKR from 0.86% in 2001 to 0.45% in 2011 and decreased for THR from 0.55% to 0.24% for the same period. Patients who developed a DVT after TKR were older (67.7 vs. 66.8, P < 0.001); more likely to be African American (P < 0.001); and more likely to have significant comorbidities including congestive heart failure, peripheral artery disease, and end-stage renal disease. Findings were similar for patients who developed a DVT after THR. Mortality was significantly greater for patients who developed a DVT (0.4% for TKR and 1.7% for THR), with an almost double LOS.
CONCLUSIONS: A focus on DVT prophylaxis may have decreased national rates of DVT after TKR and THR. Older patients, African Americans, and patients with more comorbidities appear to be especially at risk for DVT. Mortality is almost 4 to 8 times higher for patients with DVT, and LOS is double. A focus on DVT prophylaxis and perhaps more aggressive management of the at-risk population may further help decrease the rate of DVT.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27531085     DOI: 10.1016/j.avsg.2016.05.110

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  10 in total

1.  Rate of venous thromboembolism after surgical treatment of proximal humerus fractures.

Authors:  Jessica H Heyer; Rachel L Parker; Thomas Lynch; Torrey Parry; Andrew S Neviaser
Journal:  Arch Orthop Trauma Surg       Date:  2020-06-05       Impact factor: 3.067

2.  Role of arthroplasty in the Jehovah's Witness population.

Authors:  Jay L Mottla; Jordan P Murphy; Laura E Keeling; Richard Verstraete; Mark W Zawadsky
Journal:  Eur J Orthop Surg Traumatol       Date:  2021-01-03

3.  Association of Aspirin With Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty Compared With Other Anticoagulants: A Noninferiority Analysis.

Authors:  Brandon R Hood; Mark E Cowen; Huiyong T Zheng; Richard E Hughes; Bonita Singal; Brian R Hallstrom
Journal:  JAMA Surg       Date:  2019-01-01       Impact factor: 14.766

4.  Perioperative Blood Transfusions Are Associated with a Higher Incidence of Thromboembolic Events After TKA: An Analysis of 333,463 TKAs.

Authors:  Alexander J Acuña; Daniel Grits; Linsen T Samuel; Ahmed K Emara; Atul F Kamath
Journal:  Clin Orthop Relat Res       Date:  2021-03-01       Impact factor: 4.755

5.  Plasminogen activator inhibitor-1: a risk factor for deep vein thrombosis after total hip arthroplasty.

Authors:  Ju Tang; Wei Zhu; Xiaoliang Mei; Zhenxiang Zhang
Journal:  J Orthop Surg Res       Date:  2018-01-10       Impact factor: 2.359

6.  A Strategy of Continued Antiplatelet Agents, Vitamin K Antagonists, and Direct Oral Anticoagulants Throughout the Perioperative Period of Total Knee Arthroplasty in Patients Receiving Chronic Antithrombotic Therapy.

Authors:  Sachiyuki Tsukada; Kenji Kurosaka; Masahiro Nishino; Tetsuyuki Maeda; Naoyuki Hirasawa
Journal:  JB JS Open Access       Date:  2019-07-16

Review 7.  An Update on Venous Thromboembolism Rates and Prophylaxis in Hip and Knee Arthroplasty in 2020.

Authors:  Daniel C Santana; Ahmed K Emara; Melissa N Orr; Alison K Klika; Carlos A Higuera; Viktor E Krebs; Robert M Molloy; Nicolas S Piuzzi
Journal:  Medicina (Kaunas)       Date:  2020-08-19       Impact factor: 2.430

8.  Equivalent VTE rates after total joint arthroplasty using thromboprophylaxis with aspirin versus potent anticoagulants: retrospective analysis of 4562 cases across a diverse healthcare system.

Authors:  Chelsea Matzko; Zachary P Berliner; Gregg Husk; Bushra Mina; Barton Nisonson; Matthew S Hepinstall
Journal:  Arthroplasty       Date:  2021-12-03

9.  Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio for acute deep vein thrombosis after total joint arthroplasty: a retrospective study.

Authors:  Chen Yao; Zhe Zhang; Yao Yao; Xingquan Xu; Qing Jiang; Dongquan Shi
Journal:  J Orthop Surg Res       Date:  2018-02-27       Impact factor: 2.359

10.  Complications to 6 months following total hip or knee arthroplasty: observations from an Australian clinical outcomes registry.

Authors:  Sung Mu Heo; Ian Harris; Justine Naylor; Adriane M Lewin
Journal:  BMC Musculoskelet Disord       Date:  2020-09-10       Impact factor: 2.362

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.